The USU Center for Biotechnology’s On-Demand Blood program provides a potentially transformative alternative for traditional donated blood for the Department of Defense. BETHESDA, MD – The Geneva Foundation (Geneva), a 501(c)3 non-profit that provides innovative scientific research and exceptional program management, announces today the award of an additional $12 million dollars by the Uniformed
The translational research program is a collaboration between The Geneva Foundation, Uniformed Services University (USU), The Wellman Center for Photomedicine at Massachusetts General Hospital (MGH), Henry M. Jackson Foundation (HJF), Spaulding Rehabilitation, and Litecure (now DJO). The Geneva Foundation (Geneva), a non-profit dedicated to advancing military medicine, announces today the implementation of a new
Geneva’s Researcher of the Year award is presented annually by Geneva’s Scientific Advisory Board to a researcher who exemplifies Geneva’s mission of advancing innovative medical research within the U.S. military, for the benefit of U.S. service members and veterans, their families, and the global community. Kenneth Cameron, PhD, MPH, ATC has been named The Geneva
The award, funded by the U.S. Army, was accepted on behalf of Geneva-funded researcher V. Sujith Sajja, PhD BETHESDA, Md. – The Geneva Foundation (Geneva), a 501(c)3 non-profit that provides innovative scientific research and exceptional program management, announces today the award of a $2.1 million dollar cooperative agreement from the U.S. Army Medical Research Acquisition
TACOMA, Wash. – The Geneva Foundation (Geneva), a 501(c)3 non-profit that provides innovative scientific research and exceptional program management, announces today the award of GSA Schedule (Contract No. 47QRAA21D009K) under the Multiple Award Schedule (MAS) from the General Services Administration (GSA) to further advance military medical research. Geneva’s government-wide MAS contract has an award period
Geneva is proud to be a founding member of the consortium which brings together a wealth of resources in North Carolina to provide world-class solutions for the military. Published by: RTI International Publish Date: 25 August 2021 RESEARCH TRIANGLE PARK, N.C. — A newly launched consortium led by RTI International and comprised of
Geneva has been selected to support a monoclonal antibody protocol under this public-private partnership at two military treatment facilities. TACOMA, WA – The Geneva Foundation (Geneva) announces today it has entered into a Cooperative Research and Development Agreement (CRADA) to conduct clinical trials at two military treatment facilities under the Accelerating COVID-19 Therapeutic Interventions
The Geneva Foundation (Geneva) is partnering with National Cancer Institute (NCI) scientists and the U.S. Army on two investigational grants for breast cancer research using novel antibody-drug conjugates. Geneva Principal Investigator Martin J. Schenermann, PhD, a senior investigator at the National Cancer Institute (NCI) and Principal Investigator Brad St. Croix, PhD, a senior scientist also at
The USU-4DBio3 Center for Biotechnology, administered by Geneva, ensures warfighters are supported with cutting-edge technologies. BETHESDA, MD – The Geneva Foundation (Geneva) announces today the official designation of the Biotechnology, Biomanufacturing, and Bioprinting Program (4DBio3) as a Uniformed Services University (USU) Center. The USU-4DBio3 Center for Biotechnology, derived from the 4DBio3 Program and administered by The
COL (Ret.) Kent Kester, MD is appointed as the SAB’s Board Chair. The Geneva Foundation (Geneva) announces today the appointment of four new members to its Scientific Advisory Board (SAB) which provides scientific consult, advisement, and direction to Geneva’s senior leadership, program directors, principal investigators, and research administrators. “It is a great honor to